Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab

BACKGROUND: In-depth immunogenicity studies of tixagevimab-cilgavimab (T-C) are lacking, including following breakthrough coronavirus disease 2019 (COVID-19) in vaccinated patients with hematologic malignancy (HM) receiving T-C as pre-exposure prophylaxis. METHODS: We performed a prospective, observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Victoria G, Nguyen, Thi H O, Allen, Lilith F, Rowntree, Louise C, Kedzierski, Lukasz, Chua, Brendon Y, Lim, Chhay, Saunders, Natalie R, Klimevski, Emily, Tennakoon, Gayani S, Seymour, John F, Wadhwa, Vikas, Cain, Natalie, Vo, Kim L, Nicholson, Suellen, Karapanagiotidis, Theo, Williamson, Deborah A, Thursky, Karin A, Spelman, Timothy, Yong, Michelle K, Slavin, Monica A, Kedzierska, Katherine, Teh, Benjamin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644824/
https://www.ncbi.nlm.nih.gov/pubmed/38023562
http://dx.doi.org/10.1093/ofid/ofad550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644824/
https://www.ncbi.nlm.nih.gov/pubmed/38023562
http://dx.doi.org/10.1093/ofid/ofad550

Ejemplares similares